|
|
|
94TH GENERAL ASSEMBLY
State of Illinois
2005 and 2006 SB2589
Introduced 1/20/2006, by Sen. John J. Millner SYNOPSIS AS INTRODUCED: |
|
720 ILCS 570/204 |
from Ch. 56 1/2, par. 1204 |
|
Amends the Illinois Controlled Substances Act. Provides that Salvia divinorum is a Schedule I controlled substance.
|
| |
|
|
| CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY | |
|
|
A BILL FOR
|
|
|
|
|
SB2589 |
|
LRB094 18565 RLC 53900 b |
|
|
1 |
| AN ACT concerning criminal law.
|
2 |
| Be it enacted by the People of the State of Illinois,
|
3 |
| represented in the General Assembly:
|
4 |
| Section 5. The Illinois Controlled Substances Act is |
5 |
| amended by changing Section 204 as follows:
|
6 |
| (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
|
7 |
| Sec. 204. (a) The controlled substances listed in this |
8 |
| Section are
included in Schedule I.
|
9 |
| (b) Unless specifically excepted or unless listed in |
10 |
| another
schedule, any of the following opiates, including their |
11 |
| isomers,
esters, ethers, salts, and salts of isomers, esters, |
12 |
| and ethers,
whenever the existence of such isomers, esters, |
13 |
| ethers and salts is
possible within the specific chemical |
14 |
| designation:
|
15 |
| (1) Acetylmethadol;
|
16 |
| (1.1) Acetyl-alpha-methylfentanyl
|
17 |
| (N-[1-(1-methyl-2-phenethyl)-
|
18 |
| 4-piperidinyl]-N-phenylacetamide);
|
19 |
| (2) Allylprodine;
|
20 |
| (3) Alphacetylmethadol, except
|
21 |
| levo-alphacetylmethadol (also known as levo-alpha-
|
22 |
| acetylmethadol, levomethadyl acetate, or LAAM);
|
23 |
| (4) Alphameprodine;
|
24 |
| (5) Alphamethadol;
|
25 |
| (6) Alpha-methylfentanyl
|
26 |
| (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
27 |
| propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
|
28 |
| propanilido) piperidine;
|
29 |
| (6.1) Alpha-methylthiofentanyl
|
30 |
| (N-[1-methyl-2-(2-thienyl)ethyl-
|
31 |
| 4-piperidinyl]-N-phenylpropanamide);
|
32 |
| (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
|
|
|
|
SB2589 |
- 2 - |
LRB094 18565 RLC 53900 b |
|
|
1 |
| (7) 1-methyl-4-phenyl-4-proprionoxypiperidine (MPPP);
|
2 |
| (7.1) PEPAP
|
3 |
| (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
|
4 |
| (8) Benzethidine;
|
5 |
| (9) Betacetylmethadol;
|
6 |
| (9.1) Beta-hydroxyfentanyl
|
7 |
| (N-[1-(2-hydroxy-2-phenethyl)-
|
8 |
| 4-piperidinyl]-N-phenylpropanamide);
|
9 |
| (10) Betameprodine;
|
10 |
| (11) Betamethadol;
|
11 |
| (12) Betaprodine;
|
12 |
| (13) Clonitazene;
|
13 |
| (14) Dextromoramide;
|
14 |
| (15) Diampromide;
|
15 |
| (16) Diethylthiambutene;
|
16 |
| (17) Difenoxin;
|
17 |
| (18) Dimenoxadol;
|
18 |
| (19) Dimepheptanol;
|
19 |
| (20) Dimethylthiambutene;
|
20 |
| (21) Dioxaphetylbutyrate;
|
21 |
| (22) Dipipanone;
|
22 |
| (23) Ethylmethylthiambutene;
|
23 |
| (24) Etonitazene;
|
24 |
| (25) Etoxeridine;
|
25 |
| (26) Furethidine;
|
26 |
| (27) Hydroxpethidine;
|
27 |
| (28) Ketobemidone;
|
28 |
| (29) Levomoramide;
|
29 |
| (30) Levophenacylmorphan;
|
30 |
| (31) 3-Methylfentanyl
|
31 |
| (N-[3-methyl-1-(2-phenylethyl)-
|
32 |
| 4-piperidyl]-N-phenylpropanamide);
|
33 |
| (31.1) 3-Methylthiofentanyl
|
34 |
| (N-[(3-methyl-1-(2-thienyl)ethyl-
|
35 |
| 4-piperidinyl]-N-phenylpropanamide);
|
36 |
| (32) Morpheridine;
|
|
|
|
SB2589 |
- 3 - |
LRB094 18565 RLC 53900 b |
|
|
1 |
| (33) Noracymethadol;
|
2 |
| (34) Norlevorphanol;
|
3 |
| (35) Normethadone;
|
4 |
| (36) Norpipanone;
|
5 |
| (36.1) Para-fluorofentanyl
|
6 |
| (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
7 |
| 4-piperidinyl]propanamide);
|
8 |
| (37) Phenadoxone;
|
9 |
| (38) Phenampromide;
|
10 |
| (39) Phenomorphan;
|
11 |
| (40) Phenoperidine;
|
12 |
| (41) Piritramide;
|
13 |
| (42) Proheptazine;
|
14 |
| (43) Properidine;
|
15 |
| (44) Propiram;
|
16 |
| (45) Racemoramide;
|
17 |
| (45.1) Thiofentanyl
|
18 |
| (N-phenyl-N-[1-(2-thienyl)ethyl-
|
19 |
| 4-piperidinyl]-propanamide);
|
20 |
| (46) Tilidine;
|
21 |
| (47) Trimeperidine;
|
22 |
| (48) Beta-hydroxy-3-methylfentanyl (other name:
|
23 |
| N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
|
24 |
| N-phenylpropanamide).
|
25 |
| (c) Unless specifically excepted or unless listed in |
26 |
| another
schedule, any of the following opium derivatives, its |
27 |
| salts, isomers
and salts of isomers, whenever the existence of |
28 |
| such salts, isomers and
salts of isomers is possible within the |
29 |
| specific chemical designation:
|
30 |
| (1) Acetorphine;
|
31 |
| (2) Acetyldihydrocodeine;
|
32 |
| (3) Benzylmorphine;
|
33 |
| (4) Codeine methylbromide;
|
34 |
| (5) Codeine-N-Oxide;
|
35 |
| (6) Cyprenorphine;
|
36 |
| (7) Desomorphine;
|
|
|
|
SB2589 |
- 4 - |
LRB094 18565 RLC 53900 b |
|
|
1 |
| (8) Diacetyldihydromorphine (Dihydroheroin);
|
2 |
| (9) Dihydromorphine;
|
3 |
| (10) Drotebanol;
|
4 |
| (11) Etorphine (except hydrochloride salt);
|
5 |
| (12) Heroin;
|
6 |
| (13) Hydromorphinol;
|
7 |
| (14) Methyldesorphine;
|
8 |
| (15) Methyldihydromorphine;
|
9 |
| (16) Morphine methylbromide;
|
10 |
| (17) Morphine methylsulfonate;
|
11 |
| (18) Morphine-N-Oxide;
|
12 |
| (19) Myrophine;
|
13 |
| (20) Nicocodeine;
|
14 |
| (21) Nicomorphine;
|
15 |
| (22) Normorphine;
|
16 |
| (23) Pholcodine;
|
17 |
| (24) Thebacon.
|
18 |
| (d) Unless specifically excepted or unless listed in |
19 |
| another
schedule, any material, compound, mixture, or |
20 |
| preparation which contains
any quantity of the following |
21 |
| hallucinogenic substances, or which
contains any of its salts, |
22 |
| isomers and salts of isomers, whenever the
existence of such |
23 |
| salts, isomers, and salts of isomers is possible
within the |
24 |
| specific chemical designation (for the purposes of this
|
25 |
| paragraph only, the term "isomer" includes the optical, |
26 |
| position and
geometric isomers):
|
27 |
| (1) 3,4-methylenedioxyamphetamine
|
28 |
| (alpha-methyl,3,4-methylenedioxyphenethylamine,
|
29 |
| methylenedioxyamphetamine, MDA);
|
30 |
| (1.1) Alpha-ethyltryptamine
|
31 |
| (some trade or other names: etryptamine;
|
32 |
| MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
33 |
| 3-(2-aminobutyl)indole; a-ET; and AET);
|
34 |
| (2) 3,4-methylenedioxymethamphetamine (MDMA);
|
35 |
| (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
36 |
| (also known as: N-ethyl-alpha-methyl-
|
|
|
|
SB2589 |
- 5 - |
LRB094 18565 RLC 53900 b |
|
|
1 |
| 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
2 |
| and MDEA);
|
3 |
| (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
|
4 |
| (4) 3,4,5-trimethoxyamphetamine (TMA);
|
5 |
| (5) (Blank);
|
6 |
| (6) Diethyltryptamine (DET);
|
7 |
| (7) Dimethyltryptamine (DMT);
|
8 |
| (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
|
9 |
| (9) Ibogaine (some trade and other names:
|
10 |
| 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
11 |
| 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
12 |
| indole; Tabernanthe iboga);
|
13 |
| (10) Lysergic acid diethylamide;
|
14 |
| (10.5) Salvia divinorum;
|
15 |
| (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
|
16 |
| (12) Peyote (meaning all parts of the plant presently |
17 |
| classified
botanically as Lophophora williamsii
williemaii
|
18 |
| Lemaire, whether growing or not, the
seeds thereof, any |
19 |
| extract from any part of that plant, and every compound,
|
20 |
| manufacture, salts, derivative, mixture, or preparation of |
21 |
| that plant, its
seeds or extracts);
|
22 |
| (13) N-ethyl-3-piperidyl benzilate (JB 318);
|
23 |
| (14) N-methyl-3-piperidyl benzilate;
|
24 |
| (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
25 |
| (also known as N-hydroxy-alpha-methyl-
|
26 |
| 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
|
27 |
| (15) Parahexyl; some trade or other names:
|
28 |
| 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
29 |
| dibenzo (b,d) pyran; Synhexyl;
|
30 |
| (16) Psilocybin;
|
31 |
| (17) Psilocyn;
|
32 |
| (18) Alpha-methyltryptamine (AMT);
|
33 |
| (19) 2,5-dimethoxyamphetamine
|
34 |
| (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
|
35 |
| (20) 4-bromo-2,5-dimethoxyamphetamine
|
36 |
| (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
|
|
|
SB2589 |
- 6 - |
LRB094 18565 RLC 53900 b |
|
|
1 |
| 4-bromo-2,5-DMA);
|
2 |
| (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
3 |
| Some trade or other names: 2-(4-bromo-
|
4 |
| 2,5-dimethoxyphenyl)-1-aminoethane;
|
5 |
| alpha-desmethyl DOB, 2CB, Nexus;
|
6 |
| (21) 4-methoxyamphetamine
|
7 |
| (4-methoxy-alpha-methylphenethylamine;
|
8 |
| paramethoxyamphetamine; PMA);
|
9 |
| (22) (Blank);
|
10 |
| (23) Ethylamine analog of phencyclidine.
|
11 |
| Some trade or other names:
|
12 |
| N-ethyl-1-phenylcyclohexylamine,
|
13 |
| (1-phenylcyclohexyl) ethylamine,
|
14 |
| N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
|
15 |
| (24) Pyrrolidine analog of phencyclidine. Some trade |
16 |
| or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
17 |
| PHP;
|
18 |
| (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
|
19 |
| (26) 2,5-dimethoxy-4-ethylamphetamine
|
20 |
| (another name: DOET);
|
21 |
| (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
22 |
| (another name: TCPy);
|
23 |
| (28) (Blank);
|
24 |
| (29) Thiophene analog of phencyclidine (some trade
|
25 |
| or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
26 |
| 2-thienyl analog of phencyclidine; TPCP; TCP);
|
27 |
| (30) Bufotenine (some trade or other names:
|
28 |
| 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
29 |
| 3-(2-dimethylaminoethyl)-5-indolol;
|
30 |
| 5-hydroxy-N,N-dimethyltryptamine;
|
31 |
| N,N-dimethylserotonin; mappine).
|
32 |
| (e) Unless specifically excepted or unless listed in |
33 |
| another
schedule, any material, compound, mixture, or |
34 |
| preparation which contains
any quantity of the following |
35 |
| substances having a depressant effect on
the central nervous |
36 |
| system, including its salts, isomers, and salts of
isomers |
|
|
|
SB2589 |
- 7 - |
LRB094 18565 RLC 53900 b |
|
|
1 |
| whenever the existence of such salts, isomers, and salts of
|
2 |
| isomers is possible within the specific chemical designation:
|
3 |
| (1) mecloqualone;
|
4 |
| (2) methaqualone; and
|
5 |
| (3) gamma hydroxybutyric acid.
|
6 |
| (f) Unless specifically excepted or unless listed in |
7 |
| another schedule,
any material, compound, mixture, or |
8 |
| preparation which contains any quantity
of the following |
9 |
| substances having a stimulant effect on the central nervous
|
10 |
| system, including its salts, isomers, and salts of isomers:
|
11 |
| (1) Fenethylline;
|
12 |
| (2) N-ethylamphetamine;
|
13 |
| (3) Aminorex (some other names:
|
14 |
| 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
15 |
| 4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
16 |
| salts, optical isomers, and salts of optical isomers;
|
17 |
| (4) Methcathinone (some other names:
|
18 |
| 2-methylamino-1-phenylpropan-1-one;
|
19 |
| Ephedrone; 2-(methylamino)-propiophenone;
|
20 |
| alpha-(methylamino)propiophenone; N-methylcathinone;
|
21 |
| methycathinone; Monomethylpropion; UR 1431) and its
|
22 |
| salts, optical isomers, and salts of optical isomers;
|
23 |
| (5) Cathinone (some trade or other names:
|
24 |
| 2-aminopropiophenone; alpha-aminopropiophenone;
|
25 |
| 2-amino-1-phenyl-propanone; norephedrone);
|
26 |
| (6) N,N-dimethylamphetamine (also known as:
|
27 |
| N,N-alpha-trimethyl-benzeneethanamine;
|
28 |
| N,N-alpha-trimethylphenethylamine);
|
29 |
| (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
30 |
| 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine).
|
31 |
| (g) Temporary listing of substances subject to emergency |
32 |
| scheduling.
Any material, compound, mixture, or preparation |
33 |
| that contains any quantity
of the following substances:
|
34 |
| (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
35 |
| (benzylfentanyl), its optical isomers, isomers, salts,
|
36 |
| and salts of isomers;
|